Lyell Immunopharma (LYEL) AI Stock Analysis

• Market Cap: $131.28M
• Dividend Yield: N/A
• Average Volume (3M): 820.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.90
• Revenue Growth: -53.08%
• EPS Growth: -40.31%
• Country: US
• Employees: 300
• Sector: Healthcare
• Sector Strength: 71
• Industry: Biotechnology
• EPS (TTM): -1.31
• Shares Outstanding: 295,283,660
• 10 Day Avg. Volume: 694,545
• 30 Day Avg. Volume: 820,918
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 2799.83
• Price to Cash Flow (P/CF): -0.90
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $1.00
• Price Target Upside: 117.39% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 2

Lyell Immunopharma's overall stock score reflects significant financial and technical challenges. The company's inability to generate revenue and operational losses are major concerns, impacting financial performance and valuation. The technical analysis indicates weak market momentum, further weighing on the stock's prospects. Despite a somewhat solid balance sheet, the high operational risks necessitate strategic shifts to improve performance. The score reflects the need for caution and potential restructuring to address financial and operational hurdles.

Positive Factors

Financial Performance

Lyell ended 4Q24 with $383.5 million in cash, which management expects to provide an operational runway into 2027.

Product Development

Optimism is growing for next-gen LYL119’s improved therapeutic window.

Negative Factors

Competitive Landscape

Competing with established players like Gilead, Bristol, and Novartis is likely to be challenging, especially given their sizeable infrastructure investments.

Market Position

The CD19-targeted CAR-T space is crowded, and the opportunity for another entrant like Lyell is limited.

Strategic Uncertainty

The decision to discontinue next-gen, early-stage, solid tumor CAR-T LYL119 adds to the uncertainty surrounding Lyell's strategy.

Lyell Immunopharma Business Overview & Revenue Model

Company Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

How the Company Makes Money

Lyell Immunopharma primarily generates revenue through collaboration agreements and strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development or regulatory goals, and potential royalties from product sales. As a pre-commercial stage company, Lyell does not yet have products on the market, so its earnings are largely dependent on external funding sources, including research grants and investments from venture capital firms. Additionally, Lyell may engage in licensing agreements that allow other companies to use its proprietary technologies, further contributing to its revenue streams.

Lyell Immunopharma Financial Statement Overview

Summary

Lyell Immunopharma faces significant financial challenges, mainly due to zero revenue generation and persistent operational losses. The balance sheet is stronger with low debt, but cash flow is strained, relying heavily on financing. This reflects high operational risk and a need for strategic changes.

Income Statement

Lyell Immunopharma has faced significant challenges in revenue generation, with revenue dropping to zero in the latest year. The company has consistently reported negative net income, resulting in negative net profit margins. The absence of revenue and persistent losses indicate financial difficulties in scaling operations or commercializing products.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio, reflecting financial prudence. However, the decline in stockholders' equity over the years may indicate operational challenges. The equity ratio remains healthy, suggesting solid capital management despite operational losses.

Cash Flow

Lyell Immunopharma's cash flow statement highlights significant operating cash outflows due to ongoing losses. While free cash flow remains negative, the company has maintained a consistent level of cash reserves. The ability to generate positive cash flow from financing activities has been crucial in sustaining operations.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
61.00K	130.00K	84.68M	10.65M	7.76M
	Gross Profit
61.00K	130.00K	68.22M	-3.88M	281.00K
	EBIT
-3.31M	-247.01M	-183.12M	-214.78M	-211.94M
	EBITDA
-3.31M	-226.76M	-166.65M	-199.94M	-207.64M
	Net Income Common Stockholders
-342.99M	-234.63M	-4.75M	-285.50M	-198.53M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
370.53M	546.22M	640.15M	614.79M	612.62M
	Total Assets
490.86M	750.03M	937.56M	1.13B	908.28M
	Total Debt
50.99M	63.17M	67.70M	67.82M	54.57M
	Net Debt
-54.60M	-82.48M	-55.85M	-226.01M	-85.83M
	Total Liabilities
108.03M	95.08M	104.31M	197.62M	189.84M
	Stockholders Equity
382.82M	654.95M	833.25M	929.79M	718.44M
Cash Flow		Free Cash Flow
-162.86M	-166.38M	-193.83M	-191.75M	-212.35M
	Operating Cash Flow
-162.39M	-163.69M	-169.56M	-126.25M	-160.87M
	Investing Cash Flow
122.42M	184.05M	-11.54M	-121.57M	-273.52M
	Financing Cash Flow
1.33M	1.74M	10.63M	401.24M	476.79M

Lyell Immunopharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.46
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Neutral. The current price of 0.46 is below the 20-day moving average (MA) of 0.50, below the 50-day MA of 0.58, and below the 200-day MA of 1.00, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.06 is Neutral, neither overbought nor oversold. The STOCH value of 42.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for LYEL.

Lyell Immunopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
SEER	45 Neutral	$124.94M	―	-23.91%	―	-13.92%	-2.86%
NKTX	43 Neutral	$111.76M	―	-31.94%	―	―	30.76%
FATE	42 Neutral	$105.93M	―	-54.21%	―	-78.55%	-0.92%
ADCT	41 Neutral	$120.01M	―	123.38%	―	1.84%	43.40%
LYEL	40 Underperform	$131.28M	―	-66.10%	―	-53.08%	-40.31%
FDMT	27 Underperform	$128.72M	―	-25.95%	―	―	―

Lyell Immunopharma Corporate Events

Lyell Immunopharma’s LyFE Center Begins IMPT-314 Production

Following FDA clearance, Lyell Immunopharma’s LyFE manufacturing center in Bothell, Washington, is now producing IMPT-314 for a Phase 1/2 clinical trial targeting relapsed/refractory aggressive large B-cell lymphoma. The company plans to close its West Hills facility, acquired in 2024, resulting in a workforce reduction of approximately 73 employees and expected costs of $3.0 million to $4.0 million. Additionally, Chief Business Officer Matthew Lang announced his resignation, effective April 13, 2025, but will remain as an advisor until September 30, 2025. Lyell maintains its financial guidance, projecting a net cash use of $175 million to $185 million in 2025, ensuring operational runway into 2027.